Dr Wilmott is a current NHMRC research fellow, 2020 NHMRC investigator fellow, senior lecturer at The University of Sydney and research leader of the Melanoma Translational Pathology Research Group (MTPRG) at the Charles Perkins Center, The University of Sydney. Dr Wilmott leads the large 25+ research team whose research interests spans areas such as primary melanoma diagnosis, melanoma biology, systemic therapies in advanced disease and more recently the development of personalized immunotherapies for metastatic melanoma. Dr Wilmott is internationally recognized as an emerging expert in clinical implications of genomic profiles (First author Nature and Int J Cancer), immune profiling of cancer tissue (Co-author in Nature, The Lancet Oncology, senior author in Clinical Cancer Research and Oncoimmunology) and in biomarker discovery of systemic therapies (Senior author Cancer Cell). Dr Wilmott co-leads multople international programs of research that have made significant contributions to the knowledge in the melanoma genomics. This includes research that has described in unprecedented detail the somatic mutations that occur in a large cohort of cutaneous melanomas and melanomas that have arisen in mucosal (female genital and anorectal tract), acral (hands and feet) and the critical unmet need of childhood melanoma. This work has generated new knowledge with multiple publications (including in Nature, Laboratory Investigation, Oncotarget, J Invest Derm, Int J Cancer and Pathology). I am a significant contributor to this body of work as reflected by the first or senior authorship on 6/7 publications and contributed funding as CIA on grants focusing on childhood melanoma. A major focus of Dr Wilmott’s research is the integrate clinical, multi-omic and pathological data into the selection of systemic therapies for metastatic melanoma patients. Dr Wilmott is a world leader in highly multiplexed immune profiling in melanoma patients’ tissue and the correlates with transcriptomics and clinical response to immunotherapies (Cancer Cell 2019). Dr Wilmott has experience in immunotherapy drug discovery in melanoma biopsies (Clin Cancer Res 2019) and his work applies the above skills and expertise to uncover effective treatment options for the more that 50% of melanoma patients not responding to current therapies.